Conventional Transarterial Chemo embolization Using Streptozocin in Patients with Unresectable Neuroendocrine Liver Metastases

Audrey Fohlen (1, 2, 3) , Remi Beaudouin (2) , Arnaud Alvès (4, 5, 6) , Karine Bouhier-Leporrier (7) , Christophe Pasik , Jean-Pierre Pelage (1, 2)

1 ISTCT - Imagerie et Stratégies Thérapeutiques pour les Cancers et Tissus cérébraux
2 Service de Radiologie [CHU Caen]
3 Cyceron - GIP Cyceron
4 Service de Chirurgie Viscérale et Digestive [CHU Caen]
5 ANTICIPE - Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers
6 UNICANCER/CRLC - Centre Régional de Lutte contre le Cancer François Baclesse [Caen]
7 Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen]

Background: The purpose of this study was to evaluate the clinical, biological and radiological responses to, and tolerability of, conventional transarterial chemoembolization (cTACE) using streptozocin for unresectable neuroendocrine liver metastases. Patients and methods: A total of 52 patients with predominant liver disease were treated with cTACE using an emulsion of streptozocin, Lipiodol and embolization particles. A sequential approach was favored in patients with high liver tumor burden. Clinical, biological and radiological responses were evaluated using carcinoid symptoms, biomarkers and mRecist criteria, respectively. Results: A total of 127 procedures were performed with a sequential approach in 65% of patients. All patients received streptozocin and Lipiodol. Carcinoid syndrome was improved in 69% of patients after treatment (p = 0.01). Post-embolization syndrome was reported in 78% of patients. At the end of all cTACE, objective response and non-progressive disease were 32% and 70%, respectively. Progression-free survival was 18.3 ± 13.3 months (median 14.9) and median overall survival (OS) from start of treatment was 74 months. The OS at 1 year, 2 years, 3 years and 5 years was 91% (IC = 84-99%), 84% (CI = 72-95%), 69% (CI = 53-84%) and 63% (C = 46-81%), respectively. Conclusions: cTACE using streptozocin is an effective and well-tolerated palliative option for patients with neuroendocrine liver metastases, associated with prolonged survival and delayed time to progression.

Mots clés: liver metastases; neuroendocrine tumor; transarterial chemoembolization; streptozocin

Domaines: Sciences du Vivant [q-bio]

Audrey Fohlen, Remi Beaudouin, Arnaud Alvès, Karine Bouhier-Leporrier, Christophe Pasik, et al.. Conventional Transarterial Chemo embolization Using Streptozocin in Patients with Unresectable Neuroendocrine Liver Metastases. Cancers, 2023, 15 (16), ⟨10.3390/cancers15164021⟩. ⟨hal-04190556⟩